Zacks: Analysts Expect Alphatec Holdings, Inc. (NASDAQ:ATEC) Will Post Earnings of -$0.30 Per Share

Equities analysts expect Alphatec Holdings, Inc. (NASDAQ:ATECGet Rating) to announce ($0.30) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Alphatec’s earnings, with estimates ranging from ($0.40) to ($0.16). Alphatec also reported earnings of ($0.30) per share in the same quarter last year. The firm is expected to announce its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Alphatec will report full year earnings of ($1.17) per share for the current fiscal year, with EPS estimates ranging from ($1.55) to ($0.61). For the next year, analysts forecast that the company will post earnings of ($0.88) per share, with EPS estimates ranging from ($1.50) to ($0.14). Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Alphatec.

Alphatec (NASDAQ:ATECGet Rating) last released its earnings results on Tuesday, March 1st. The medical technology company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.09). Alphatec had a negative return on equity of 121.77% and a negative net margin of 60.83%. The business had revenue of $73.96 million during the quarter, compared to analysts’ expectations of $73.70 million. During the same quarter in the previous year, the business earned ($0.35) EPS.

Several equities analysts have recently commented on ATEC shares. Piper Sandler cut their price target on Alphatec from $22.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 2nd. StockNews.com started coverage on Alphatec in a research note on Thursday, March 31st. They set a “sell” rating on the stock. HC Wainwright raised their price target on Alphatec from $19.00 to $20.00 in a research note on Friday, May 6th. Finally, Zacks Investment Research lowered Alphatec from a “hold” rating to a “sell” rating in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $19.00.

Shares of Alphatec stock opened at $8.14 on Friday. The firm has a market cap of $828.33 million, a P/E ratio of -4.93 and a beta of 1.57. The company has a current ratio of 3.28, a quick ratio of 2.37 and a debt-to-equity ratio of 4.11. Alphatec has a 12 month low of $7.28 and a 12 month high of $16.47. The stock’s fifty day moving average price is $11.19 and its 200-day moving average price is $11.24.

In other Alphatec news, SVP Scott Lish sold 5,100 shares of Alphatec stock in a transaction dated Tuesday, March 1st. The stock was sold at an average price of $10.94, for a total value of $55,794.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 11,490 shares of company stock worth $122,949 in the last quarter. 34.38% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ATEC. Wells Fargo & Company MN boosted its holdings in Alphatec by 30.7% in the second quarter. Wells Fargo & Company MN now owns 131,286 shares of the medical technology company’s stock worth $2,011,000 after acquiring an additional 30,804 shares in the last quarter. Morgan Stanley boosted its holdings in Alphatec by 69.8% in the second quarter. Morgan Stanley now owns 542,189 shares of the medical technology company’s stock worth $8,306,000 after acquiring an additional 222,958 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Alphatec in the third quarter worth about $348,000. Swiss National Bank boosted its holdings in Alphatec by 2.7% in the third quarter. Swiss National Bank now owns 140,000 shares of the medical technology company’s stock worth $1,707,000 after acquiring an additional 3,700 shares in the last quarter. Finally, Barclays PLC boosted its holdings in Alphatec by 104.8% in the third quarter. Barclays PLC now owns 28,897 shares of the medical technology company’s stock worth $352,000 after acquiring an additional 14,785 shares in the last quarter. 53.52% of the stock is owned by institutional investors and hedge funds.

About Alphatec (Get Rating)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement.

Featured Stories

Get a free copy of the Zacks research report on Alphatec (ATEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.